The management of osteoporosis calls for a range of strategies, including pharmacotherapy. At a meeting organized by The Osteoporosis Society of Hong Kong, Professor Markus Seibel of the University of Sydney, Australia, reviewed current pharmacological therapies for osteoporosis.
Many patients with gastro-oesophageal reflux disease (GERD) continue to experience troublesome symptoms such as heartburn and acid regurgitation despite proton pump inhibitor (PPI) therapy. The new-generation PPI dexlansoprazole, developed with a dual delayed-release (DDR) technology, fills this treatment gap. At a symposium during the Asia-Pacific Digestive Week 2016 in Kobe, Japan, experts discussed the use of PPIs for prevention of antiplatelet drug-associated gastroduodenal injury and GERD management guidelines.
Inhaled corticosteroids (ICS) have been regarded as a cornerstone of chronic obstructive pulmonary disease (COPD) management. However, their role has limitations following reports that long-term use, especially at high doses, is associated with an increased risk of pneumonia. At a Novartis-sponsored symposium during the 21st Congress of the Asian Pacific Society of Respirology (APSR 2016) in Bangkok, Thailand, Dr Chin-Kook Rhee of Seoul St Mary’s Hospital, Catholic University of Korea, discussed issues in COPD management specific to the Asia-Pacific region and how treatment goals could be met through dual bronchodilator therapy with a long-acting β2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), such as indacaterol in combination with glycopyrronium (Ultibro®, Novartis).